TechForce Robotics, a subsidiary of Nightfood Holdings, said June 1 it has completed Phase 1 of its joint development agreement with Oncotelic Therapeutics, marked by the initial deployment of its LIM-E autonomous laboratory support robot. The rollout takes TechForce's AI-enabled mobile robotics platform beyond hospitality and service-industry applications and into pharmaceutical and laboratory automation for the first time.
What LIM-E does
LIM-E is a specialized configuration of TechForce's autonomous mobile robotics platform, engineered for approved laboratory-logistics workflows. It transports approved laboratory supplies and properly contained materials between designated operational zones inside Oncotelic facilities. The deployment focuses on the kind of repetitive, low-risk, high-traffic transport work that today consumes lab-technician time and creates inconsistent handoffs across shifts.
From service robotics to GMP-regulated environments
TechForce's platform has been validated in hospitality settings and service-industry vertical applications. Moving the same architecture into a GMP-regulated environment requires additional controls — chain-of-custody logging, environmental compatibility, validated software change-management — work the two companies began under their joint development agreement in April 2026. Phase 1 deployment validates that the platform meets the operational tolerances needed inside Oncotelic's lab footprint.
Strategic stakes for Nightfood and Oncotelic
For Nightfood (parent of TechForce), the deployment opens a high-margin pharma and laboratory automation vertical alongside existing hospitality customers. For Oncotelic — a clinical-stage oncology and immunotherapy company developing late-stage candidates for high-unmet-need cancers and rare pediatric indications — the rollout shows how mid-cap biopharmas are starting to use mobile robotics to compress lab logistics overhead without taking on Siemens- or ABB-class system integrators.
Where this sits in the hospital automation race
The deployment lands during a broad acceleration in hospital and pharma automation. The global hospital robotics (logistics and pharmacy) market reached roughly $5.4 billion in 2025 and is projected to grow at a 13%+ CAGR through 2033. Adjacent moves include large surgical-robot programs like Johnson & Johnson's Ottava de novo study, and continued FDA workflow build-outs around platforms like the CMR Surgical Versius Plus.
What's next under the JDA
The two companies will use the Phase 1 deployment as a reference site for follow-on phases targeting broader GMP-relevant workflows, including support of pharmaceutical manufacturing and additional laboratory operations. TechForce said the deployment validates LIM-E as a platform for expansion across additional Oncotelic and third-party pharma sites.
Reporting based on coverage from GlobeNewswire, StockTitan, citybuzz and The Manila Times.